Michelle Yeoh featured in first look at Star Trek: Section 31, plus the return of a character who hasn’t been seen in over 30 years.
Star Trek: Section 31 recently wrapped production, and Variety has the first look at Michelle Yeoh as Philippa Georgiou in the upcoming Paramount+ movie. The sprawling cover story (which is well worth a read) also spills on the surprising return of a character who hasn’t been seen in over thirty years.
The Star Trek: Section 31 first look features Michelle Yeoh as the morally dubious Georgiou having a word with someone with a few cybernetic enhancements. The last we saw of the character was on Star Trek: Discovery when she stepped through a portal to somewhere in the past. The exact timeframe remains unknown, but thanks to the addition of one particular Star Trek character, we may have a much better idea.
Section 31 will include a younger version of Rachel Garrett, the future captain of the USS Enterprise C, who was introduced in Yesterday’s Enterprise, one of the best episodes of Star Trek: The Next Generation. The character was briefly seen as a statue in Star Trek: Picard but hasn’t been seen in the flesh since that TNG episode. She’ll be played by Kacey Rohl (Hannibal) in Section 31. The addition of Rachel Garrett puts the timeframe of Section 31 somewhere between the TOS movies and the beginning of TNG, an era which hasn’t been explored all that much.
The inclusion of a character like Garrett might not mean much to newcomers, but franchise producer Alex Kurtzman knows they can’t forget about long-time fans. “You cannot create new fans to the exclusion of old fans,” Kurtzman said. “You must serve your primary fan base first and you must keep them happy. That is one of the most important steps to building new fans.“
Section 31 screenwriter Craig Sweeny knows that the black-ops organization has been controversial with fans since its introduction in Deep Space Nine. “The concept is almost antagonistic to some of the values of Star Trek,” Sweeny said. “Famously, there’s a spot for everybody in Roddenberry’s utopia, so I was like, ‘Well, who would be the people who don’t quite fit in?’ I didn’t want to make the John le Carré version, where you’re in the headquarters and it’s backbiting and shades of gray. I wanted to do the people who were at the edges, out in the field. These are not people who necessarily work together the way you would see on a ‘Star Trek’ bridge.“
Should the movie prove to be a success, Michelle Yeoh has said that she’d be down for a sequel, but its success could mean more streaming movies in the franchise, including a possible follow-up to Star Trek: Picard.
Don Mancini is in the early stages of developing a new Chucky movie which would exist alongside the TV series.
You really can’t keep Chucky down. The murderous doll has been slicin’ and dicin’ for over thirty-five years, and creator Don Mancini revealed that he’s working on another new Chucky movie.
While speaking on the Scream Dreams podcast, Mancini said, “I’m actually in the early stages of working on a new Chucky movie.” In an interview earlier in the week with DJ Suss One, Mancini said that the new project “is designed to work in tandem with the TV show. You know, the ongoing attempt to try to conquer the universe with Chucky.“
Since the release of the first Child’s Play movie in 1988, the franchise has gone to some weird and wonderful places across the six sequels. So, where could this new Chucky movie take us? Some fans are hoping it will bring Chucky to where Jason Voorhees, Pinhead, and Lephrechaun have gone before him — space. The idea of Chucky in space has been kicking around for a number of years, but Mancini keeps getting asked about it. The subject was brought up yet again at the Saturn Awards earlier this year. “Everyone’s asking me that question!” Mancini said. “So, MY question is, ‘Do you want him to go to space? Do you personally want him to go? If there’s enough of a demand for that, eventually — I don’t know how quickly — I have an idea for that.“
With the exception of the Child’s Play remake, it’s somewhat remarkable that the franchise has kept going for so many years with its original continuity, all while reinventing itself along the way. What will the future bring?
As Mancini mentioned, the potential new movie is still in the early stages, but in the meantime, fans have the Chucky TV series to keep them occupied. The second half of the third season will debut on April 10th, and the recent trailer looks pretty outrageous. The third season has seen Chucky set up shop at the White House with America’s First Family. You can check out a review from our own Alex Maidy right here.
What would you like to see in the new Chucky movie? Do you really want to see him go to space, or would you prefer something more grounded?
Florence Pugh shares a video from the set of Marvel’s Thunderbolts, which is currently in production in Atlanta.
Marvel’s Thunderbolts movie is now in production in Atlanta, and Florence Pugh has shared a sneaky little set video on Instagram, which honestly shows off more than I would have expected. Those Marvel snipers must have been on break.
The Thunderbolts set video begins with Pugh exiting her trailer in full costume, with her hair looking shorter than it was in Black Widow. As she moves into the Atlanta studio, we see pieces of large sets before she comes across director Jake Schreier. You can see the Thunderbolts logo on the back of a chair as well as a brief snippet of footage on the monitor, which shows Yelena pointing a gun at someone. With any other movie, this might not seem particularly revealing, but for a Marvel movie… well, I’d be putting my will in order.
In addition to Florence Pugh as Yelena Belova, Thunderbolts also stars Sebastian Stan as Bucky Barnes, David Harbour as Red Guardian, Julia Louis-Dreyfus as Valentina Allegra de Fontaine, Wyatt Russell as US Agent, Hannah John-Kamen as Ghost, and Olga Kurylenko as Taskmaster. Geraldine Viswanathan will also make an appearance, replacing Ayo Edebiri, who was originally attached. Lewis Pullman is also on board, taking over for Steven Yeun, who was said to be playing The Sentry before he had to leave. Production was originally slated to kick off last summer but was delayed due to the Hollywood strikes.
Marvel is still recovering from several misfires, with Ant-Man and the Wasp: Quantumania and The Marvels underperforming. However, the studio is taking action to get things back on track, including reducing the number of projects they release. Captain America: Brave New World, which is slated to hit theaters a few months before Thunderbolts, is also undergoing some fairly extensive reshoots after poor test screenings.
Florence Pugh has had an eventful year. She appeared alongside Cillian Murphy in Christoper Nolan’s Oppenheimer and played Princess Irulan in Denis Villeneuve’s Dune: Part Two, which is currently in theaters. Thunderbolts is currently slated to hit theaters on May 2, 2025, as the last movie of Phase Five of the Marvel Cinematic Universe.
The mega-producer of many kids shows on Nickelodeon has spoken up on one aspect of the allegations made against him from his time on the network.
In the past two months, accusations of the former Nickelodeon producer, Dan Schneider, were made in a bombshell docu-series Quiet on Set: The Dark Side of Kids TV when the trailer was released, then in the show’s premiere. The two-night event chronicled the accounts of former employees who worked with Schneider on the network as he produced his slate of successful children’s programming, which include All That, Kenan & Kel, Drake & Josh, iCarly, Zoey 101 and more. Allegations were also made against the acting coach, Brian Peck, who would spend long hours with the child stars. Drake & Josh star Drake Bell became a surprise whistleblower for the show as he came forward with his accounts.
As part of the accusations, the ID show emphasizes how much Schneider played up the young actors’ looks as they were presented in an inappropriate manner. According to Variety, Schneider has now responded to the accusations made that he had aimed to sexualize young stars like Ariana Grande, Jamie Lynn Spears and Victoria Justice on his shows. A representative for Schneider said in a statement, “Everything that happened on the shows Dan ran was carefully scrutinized by dozens of involved adults, and approved by the network. If there was an actual problem with the scenes that some people, now years later are ‘sexualizing,’ they would be taken down, but they are not, they are aired constantly all over the world today still, enjoyed by both kids and parents.”
The statement continues, “Remember, all stories, dialogue, costumes, and makeup were fully approved by network executives on two coasts. A standards and practices group read and ultimately approved every script, and programming executives reviewed and approved all episodes. In addition, every day on every set, there were always parents and caregivers and their friends watching filming and rehearsals. Had there been any scenes or outfits that were inappropriate in any way, they would have been flagged and blocked by this multilayered scrutiny. Unfortunately, some adults project their adult minds onto kids’ shows, drawing false conclusions about them.”
A spokesperson for Nickelodeon would tell Variety, “Though we cannot corroborate or negate allegations of behaviors from productions decades ago, Nickelodeon as a matter of policy investigates all formal complaints as part of our commitment to fostering a safe and professional workplace environment free of harassment or other kinds of inappropriate conduct. Our highest priorities are the well-being and best interests not just of our employees, casts and crew, but of all children, and we have adopted numerous safeguards over the years to help ensure we are living up to our own high standards and the expectations of our audience.”
A trailer has been released for the upcoming Disney+ series Star Wars: The Acolyte, which is told from a villainous perspective
Yesterday, the Disney+ streaming service announced that the latest Star Wars series, Star Wars: The Acolyte, is set to premiere (with two episodes) on June 4th – and with that announcement came the promise that a trailer for the show would arrive online today. True to their word, Disney+ has now dropped a trailer for Star Wars: The Acolyte online, and you can check it out in the embed above!
Set hundreds of years before the events of Star Wars: The Phantom Menace, The Acolyte takes place during the High Republic era of the franchise. The series stars Amandla Stenberg (Bodies Bodies Bodies), Lee Jung-jae (Squid Game), Manny Jacinto (The Good Place), Dafne Keen (Logan), Charlie Barnett (You), Jodie Turner-Smith (Anne Boleyn), Rebecca Henderson (Russian Doll), Dean-Charles Chapman (Game of Thrones), Joonas Suotamon (Star Wars: The Rise of Skywalker), and Carrie-Anne Moss (The Matrix Resurrections).
Here’s the logline: An investigation into a shocking crime spree pits a respected Jedi Master (Lee) against a dangerous warrior from his past (Stenberg). As more clues emerge, they travel down a dark path where sinister forces reveal all is not what it seems.
The Acolyte creator Lesyle Headland has said that the series will flip the script from other Star Wars stories as it won’t always be told from the perspective of the Jedi. “I think that what makes this show different and interesting is that it’s from the perspective of the villains of Star Wars. These are people who are using the Force in their own way, dipping into the darker sides of the Force and are doing it without being sanctioned by the larger institution, which, in this case, is the Jedi.” Headland added that the series will feature “more Jedi than you’ve seen in any of the Star Wars content,” but also more “morally ambiguous characters” as well.
Star Wars: The Acolyte will run for eight episodes, and the first two will be available to watch as of June 4th. Will you be watching the show? What did you think of the trailer? Let us know by leaving a comment below.
WORCESTER, Pa., March 27, 2024 (Newswire.com)
-
Vision Video’s streaming platform RedeemTV is set to unveil the highly anticipated documentary The Shroud Face to Face on March 28, 2024.
The Shroud Face to Face, produced by The Nexus Institute and The Shroud LLC, is a captivating documentary that unravels the enigma of the Shroud of Turin. With cutting-edge technology and expert insights, the film provides a face-to-face encounter with this iconic relic, inviting audiences to delve into its history, authenticity, and the profound questions it raises.
This visually stunning film, based on the book The Shroud Face to Faceby acclaimed author and filmmaker Robert Orlando, offers an immersive exploration of the centuries-old mystery surrounding the Shroud of Turin and has been endorsed with high praise.
"This is a compelling and convincing account of the single most fascinating relic in the Christian world. This is for anyone seeking to understand the significance and history of the Shroud of Turin.” — Bishop Robert Barron, founder of Word on Fire
RedeemTV is a FREE, donor-supported, Christian streaming platform with over 250,000 subscribers. Streaming more than 5,000 videos, it provides family-friendly content while continuing to spread the message of Jesus.
Vision Video is a leading DVD and film distributor, committed to bringing impactful and compelling stories to audiences worldwide. With a focus on cinematic excellence, Vision Video partners with filmmakers to showcase thought-provoking narratives that inspire and captivate.
The Nexus Media focuses on TV, motion pictures, books, and screenplays, along with award- winning documentaries and shorts. Our team has years of experience in media storytelling and developing well-crafted engaging content. We invite you to view some of our past projects, The Divine Plan and Silence Patton,and participate in our new initiatives.
General Catalyst leads funding round joined by .406 Ventures, Valtruis, Mass General Brigham Ventures, and Hopelab Foundation to bolster insurance-based mental health program availability in new markets
BOSTON, March 27, 2024 (Newswire.com)
-
InStride Health, an outpatient provider of specialty pediatric anxiety and OCD treatment, announced the closing of an oversubscribed $30M Series B funding round. General Catalyst led investors and was joined by previous investors .406 Ventures, Valtruis, Mass General Brigham Ventures, and Hopelab Foundation.
The new capital enables InStride Health to continue investing in clinical quality while expanding to new markets. This will allow InStride Health to further deliver on its mission of providing insurance-based access to best-in-class mental health care. With this investment, the company's total funding has now reached $56M.
“General Catalyst is proud to partner with the mission-driven founders of InStride who have dedicated their careers to solving the adolescent mental health crisis,” says Holly Maloney, Managing Director at General Catalyst. “We believe InStride is at the forefront of helping to democratize accessible, high-quality behavioral health care through its unique clinical model and innovative approach to delivering care, and we look forward to helping them grow,” added Candace Richardson, partner at General Catalyst.
Addressing Gaps in Mental Health Treatment
Nearly one-third of youth in the United States will struggle with an anxiety disorder and/or OCD by the age of 18. This presents significant life and economic challenges for kids, their families, and the healthcare system. Providers that offer specialty care for these conditions are in short supply, often have more than six-month waitlists, and rarely accept insurance.
InStride Health accepts most major insurance plans in the states it serves, and treatment typically begins within one to four weeks of application approval — making top-tier care affordable and accessible to more young people in need. Its evidence-based care model is grounded in Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT), with an emphasis on Exposure and Response Prevention (ERP). The clinical foundation of InStride Health is based on a decade of work by its co-founders, Mona Potter, M.D., and Kathryn Boger, Ph.D., ABPP, while at McLean Hospital, the #1 psychiatric hospital according to the 2023-24 U.S. News & World Report “Best Hospitals” survey.
“As a clinician and a parent, I am incredibly grateful for the opportunity to take on the broken pediatric mental health system through our work at InStride. We’re solving a complex problem — one that requires a diverse, smart, dedicated team driven by purpose and mission — and that is the team we have been so fortunate to build,” says Dr. Potter, Chief Medical Officer and co-founder of InStride Health.
Incorporating Care into Everyday Life
The multidisciplinary care teams at InStride Health include a psychiatrist, therapist, and exposure coach, who work together throughout treatment. Unlike traditional clinical settings, InStride Health takes care out of the office, helping patients build and practice skills in the environments where their individual fears and anxieties are most present. This real-time, real-world approach accelerates learning and builds resilience.
Understanding that to best care for and support the patient, they must mobilize their community; the InStride Health team develops close, collaborative partnerships with schools, physicians, and referring providers.
Manuela Villa, Ph.D., a referring clinician from Boston Children’s Hospital, describes the power of this approach, saying, “InStride’s provision of innovative, evidence-based care and its ability to foster strategic partnerships has allowed us to work efficiently and collaboratively in the treatment of children and adolescents struggling with anxiety and OCD as well as complex medical presentations. I’ve referred many patients to the InStride team because they truly go above and beyond to ensure that all aspects of patient care are addressed, and their unique approach results in excellent patient outcomes and high levels of patient satisfaction.”
Delivering Lasting Results
InStride Health treatment is designed to be time-bound. Each personalized care plan lasts four months to one year, helping patients and their families manage anxiety and focus on building the habits and self-reliance that will prepare them for graduation from the program. Measurement-Based Care (MBC) practices ensure transparency in outcomes and data-driven treatment decisions. The outcomes are equivalent to those in top-ranked academic hospital programs; patients exhibit highly significant reductions in anxiety, functional impairment, and depression, and parents exhibit highly significant reductions in family accommodation and caregiver strain as a result of treatment, with large effect sizes across the board.
“We’re on a mission to help kids, teens, and young adults with anxiety and OCD. We aim to expand our specialty clinical services to provide the same care and accessibility we’d want for our loved ones. Thanks to the dedication of our amazing team, partners, and investors, we are thrilled to continue to expand our supportive ecosystem for the kids and families we serve,” says John Voith, Co-founder and CEO of InStride Health.
InStride Health provides specialty outpatient care for pediatric Anxiety and Obsessive Compulsive Disorder (OCD) and related presentations. Co-founded by Harvard-trained clinicians from McLean Hospital, the InStride Health care model is grounded in evidence-based treatments: Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) with an emphasis on Exposure and Response Prevention (ERP). A dedicated team of a psychiatrist, a therapist, and an exposure coach are paired with each child to provide real-time support using everyday tools like text and a video- and chat-enabled mobile application. InStride Health accepts most major insurance plans in Connecticut, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, and Rhode Island, with Maine coming soon.
ABOUT GENERAL CATALYST
General Catalyst is a venture capital firm that invests in powerful, positive change that endures — for our entrepreneurs, our investors, our people, and society. We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond to build companies that withstand the test of time. With offices in San Francisco, Palo Alto, New York City, Berlin and Boston, the firm has helped support the growth of businesses such as Airbnb, Deliveroo, Guild, Gusto, Hubspot, Illumio, Lemonade, Livongo, Oscar, Samsara, Snap, Stripe, and Warby Parker.
Contact Information:
Renee´ Hewitt
Media Contact [email protected]
917.965.8712
DURHAM, N.C., March 27, 2024 (Newswire.com)
-
Male Contraceptive Initiative has invested $500,000 in YourChoice Therapeutics, a San Francisco biotech startup, developing the first hormone-free male birth control pill. YCT-529’s first-in-human study is fully enrolled and represents a milestone in advancing reproductive health equity for men and women. More contraceptive options for men promotes shared responsibility for pregnancy prevention, impacting societal norms that have historically placed the burden of pregnancy prevention on women.
“Women’s History Month celebrates women’s achievements and offers a platform for discussing gender inequities, including contraceptive imbalances,” said Heather Vahdat, Executive Director of Male Contraceptive Initiative. “Pregnancy prevention is often viewed as 'a woman’s job,' and there are pills, patches, and devices aplenty while men’s options are extremely limited. A birth control pill for men would spark a dramatic shift that would promote shared responsibility, which we believe would foster a brighter future for women worldwide. We’re proud to support YourChoice Therapeutics’ continued success with what is currently the most advanced hormone-free male pill. We hope YCT-529’s continued success will help upend long-held biases and create a future defined by reproductive equality.”
YCT-529 is a hormone-free birth control candidate currently under investigation in a Phase 1a human clinical study. The oral drug candidate prevents sperm production by blocking access to retinoic acid - a form of vitamin A - in male testes, a mechanism that has been validated in multiple independent studies. The Phase 1a clinical study for YCT-529 began in December 2023 and includes 16 male volunteers. NIH-funded preclinical studies show YCT-529 was 99% effective and 100% reversible with no side effects.
“The future of birth control is hormone-free,” said Akash Bakshi, co-founder and CEO of YourChoice Therapeutics. “While the pill for women revolutionized birth control and remains valuable to their reproductive freedom, women have endured the side effects of hormones for more than 60 years. It’s time for men to step up, and we aim to help. We made history when we began testing the 1st hormone-free birth control candidate for men in human studies. And we’re grateful to Male Contraceptive Initiative for their support and funding which made this milestone possible. We share their vision for reproductive equality and welcome their continued support and leadership.”
Data show most men and women believe contraception is a shared responsibility. While researchers have envisioned a male birth control pill for decades, past attempts relied on suppressing testosterone to prevent sperm production. Testosterone, however, is linked to undesirable side effects: increased cardiovascular disease risk, weight gain, acne, mood changes and decreased libido. As a hormone-free male pill, YCT-529 could offer a more attractive option for men seeking convenient, reversible, effective birth control without these negative side effects.
About YCT-529
Researchers have understood for decades that vitamin A is essential for male fertility. YCT-529 is a retinoic acid receptor-alpha (RAR-a) inhibitor that prevents production of sperm cells in the testes as well as their release by blocking RAR-alpha (one of three nuclear receptors that bind retinoic acid, a form of vitamin A). Several preclinical studies have shown YCT-529 is 99% effective at preventing mouse pregnancies and 100% reversible. YourChoice Therapeutics developed YCT-529 in collaboration with Dr. Gunda Georg, a globally recognized medicinal chemist and awardee of one of the largest NIH-funded Contraceptive Centers. Male Contraceptive Initiative (MCI) has been committed to funding both the early research as well as YCT-529’s Phase 1a clinical trial in men, which is underway at Quotient Sciences in the UK. More information about the trial can be found at clinicaltrials.gov, NCT06094283.
LONDON, England, March 27, 2024 (Newswire.com)
-
Quickblox, a leading AI-powered communication platforms provider, announces the launch of its OpenAI-approved HIPAA-compliant chatbot to streamline communication safely in the healthcare industry.
Among one of the first to receive OpenAI’s HIPAA-compliant chatbot Business Associate Agreement (BAA), Quickblox is thrilled to take the next step in providing secure communication channels between patients and healthcare professionals. Quickblox’s feature-rich SDKs, APIs, and teleconsultation app can help hospitals build HIPAA-compliant telehealth platforms and streamline activities to reduce wait times, offering more flexibility to existing virtual healthcare.
Leveraging the latest advancements in AI, its HIPAA-compliant “SmartChat Assistant'' enables seamless communication while adhering to strict HIPAA regulations, safeguarding sensitive patient information. OpenAI’s BAA ensures any input the tool uses to come up with answers, such as patient requests and medical history, cannot be retained by the third party, making it completely confidential.
"We are excited to release our HIPAA-compliant chatbot, which underscores our dedication to enhancing communication in the healthcare industry," said Nate MacLeitch, CEO at Quickblox. "With the increasing demand for secure digital communication tools, our solution provides a reliable platform for healthcare providers to engage with patients while maintaining compliance with HIPAA."
The AI chatbot helps healthcare professionals by automating tasks like drafting emails, summarizing correspondence, and retrieving medical data. This frees time for healthcare professionals to focus on delivering quality patient care.
Healthcare organizations can easily add the AI chatbot to their websites with minimal coding expertise, thanks to its intuitive dashboard — empowering users to configure their specific requirements.
Moreover, the SmartChat Assistant can be trained with healthcare organizations’ unique knowledge base, becoming an expert of specific use cases. This enables patients and healthcare professionals to receive accurate and relevant responses they can trust.
Key features of the HIPAA-compliant SmartChat include:
OpenAI-approved AI technology for natural language processing
Robust encryption measures to protect sensitive data
Seamless integration with existing healthcare systems
Customizable workflows to streamline patient interactions
Reporting and analytics for performance tracking
Optional integration with QuickBlox’s other real-time communication tools or can be utilized as a standalone widget
The healthcare industry is bursting with expert medical teams, but these individuals constantly need more time in the day to treat every patient with the special care they require. Nearly half (46%) of healthcare workers reported experiencing burnout in 2022, according to the Centers for Disease Control and Prevention’s report.
Quickblox aims to bridge this gap by offering trusted digital communication tools with real-time conversation support and analytics to ensure every detail is captured and no time is wasted.
TAG Inc. proudly sponsors AdventHealth Foundation Central Florida's Sixth Annual Golf Classic, supporting vital community programs.
CHESTERFIELD, Mo., March 27, 2024 (Newswire.com)
-
TAG, Inc., a leading provider of healthcare procure-to-pay solutions, is proud to announce its sponsorship of the Sixth Annual AdventHealth Golf Classic, hosted by AdventHealth Foundation Central Florida. As a gold event sponsor, TAG, Inc. will sponsor two holes and field three teams comprising key members of AdventHealth's Finance and Supply Chain teams alongside representatives from our company.
The event, scheduled for May 10, 2024, at the Reunion Resort and Golf Club, brings together 250 community partners and AdventHealth leaders for a day of golf and philanthropy. Proceeds from the event will support AdventHealth Foundation Central Florida's mission to provide comprehensive whole-person care and ensure vital community programs continue to thrive.
John Weiss, CEO of TAG, Inc., expressed enthusiasm about the sponsorship, stating, "We are thrilled to support AdventHealth Foundation’s Annual Golf Classic. At TAG, Inc., we share AdventHealth's commitment to bringing hope and healing to our community. By sponsoring this event, we reaffirm our dedication to supporting the vital programs and services that make a difference in the lives of those we serve."
The AdventHealth Golf Classic serves as a testament to the power of collaboration and community spirit, bringing together individuals and organizations united in their mission to make a positive impact.
AdventHealth Foundation Central Florida is a 501(c)(3) not-for-profit that directly supports the AdventHealth Central Florida Division, which is made up of 17 hospitals and ERs in the four counties in and surrounding metro Orlando. As one of the largest faith-based health care systems in the United States, AdventHealth provides comprehensive whole-person care to 3.5 million patient visits in Central Florida annually.
The organization has a deep commitment to serving the community and has a local financial impact of more than $1 billion annually. AdventHealth and its employees are responsible for nearly 20 percent of Central Florida’s economy.
AdventHealth Orlando has been recognized by U.S. News & World Report, Newsweek, Centers for Medicare and Medicaid Services, and the Leapfrog Group.
About TAG, Inc.:
TAG, Inc. is a leading provider of healthcare procure-to-pay solutions dedicated to helping organizations optimize their finance and supply chain processes and drive cost savings. With a focus on innovation and efficiency, TAG, Inc. empowers healthcare providers to deliver exceptional care to their communities.
Contact Information:
Candis Spraul
Marketing, Communications & Media [email protected]
